scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Stephan Mielke | Q40593184 |
Mathias Lutz | Q53071968 | ||
P2093 | author name string | Mathias Lutz | |
P2860 | cites work | The PI3K pathway as drug target in human cancer | Q24632283 |
mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 | ||
PI3K/Akt/mTOR inhibitors in breast cancer | Q26771394 | ||
Targeting the mTOR signaling pathway in neuroendocrine tumors | Q26852089 | ||
TOR signaling in growth and metabolism | Q27860757 | ||
Defining the role of mTOR in cancer | Q28235431 | ||
Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease | Q33340454 | ||
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease | Q33364353 | ||
Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis | Q33416874 | ||
Sirolimus and everolimus in kidney transplantation | Q33423446 | ||
Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease | Q33424311 | ||
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease | Q33649332 | ||
Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. | Q33653718 | ||
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. | Q34077792 | ||
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation | Q34272554 | ||
Medical treatment of neuroendocrine tumours | Q34503867 | ||
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation | Q35184589 | ||
Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids | Q35193740 | ||
Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. | Q35231363 | ||
Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis | Q35499395 | ||
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease | Q35800856 | ||
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis | Q35900978 | ||
The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. | Q36216192 | ||
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation | Q36662042 | ||
The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial | Q36734547 | ||
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation | Q36868082 | ||
mTOR and lymphocyte metabolism | Q37137525 | ||
Comorbidity burden in patients with chronic GVHD | Q37609043 | ||
Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial. | Q37618931 | ||
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence | Q37639714 | ||
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. | Q37670062 | ||
Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment | Q38024589 | ||
mTOR, metabolism, and the regulation of T-cell differentiation and function | Q38034265 | ||
mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice | Q38092421 | ||
Drug interactions and the pharmacist: focus on everolimus | Q38113771 | ||
Current state of mTOR targeting in human breast cancer | Q38232417 | ||
Future perspectives for mTOR inhibitors in renal cell cancer treatment | Q38372445 | ||
Everolimus and sirolimus in transplantation-related but different. | Q38442560 | ||
Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature | Q38544555 | ||
The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model | Q38976077 | ||
Sjögren-Type Syndrome After Allogeneic Bone-Marrow Transplantation | Q39174395 | ||
SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo | Q41099411 | ||
Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells | Q41206823 | ||
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning | Q41876102 | ||
Rapamycin inhibits human laryngotracheal stenosis-derived fibroblast proliferation, metabolism, and function in vitro | Q41977478 | ||
Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates | Q42212846 | ||
Sirolimus for treatment of steroid-refractory acute graft-versus-host disease | Q43228479 | ||
Rapamycin for refractory acute graft-versus-host disease | Q43246106 | ||
Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus. | Q43413019 | ||
A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivors | Q43587849 | ||
Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial | Q43968027 | ||
Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation | Q44081953 | ||
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation | Q44107506 | ||
Antileukemic activity of rapamycin in acute myeloid leukemia. | Q45154681 | ||
Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study | Q46244557 | ||
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease | Q46617730 | ||
High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age. | Q47928634 | ||
GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. | Q48261069 | ||
Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. | Q51064103 | ||
Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. | Q51067478 | ||
Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control. | Q53166890 | ||
Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. | Q53550301 | ||
Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease. | Q54272726 | ||
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. | Q54596807 | ||
In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A | Q71029782 | ||
Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitro | Q71508769 | ||
The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients | Q81227390 | ||
Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors | Q84704396 | ||
[Delayed wound healing during therapy of cutaneous graft-versus-host disease with everolimus] | Q87373649 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1171-1179 | |
P577 | publication date | 2016-06-01 | |
P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
P1476 | title | New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease | |
P478 | volume | 82 |